Keywords
Endocrinology ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

1130 Search results.

Eligibility Type 2 Diabetes Weight Loss NCT01601574

- 6/20/21 - 1 form, 2 itemgroups, 39 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Weight Loss Study for People With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT01601574

Eligibility Thrombosis Type 2 Diabetes NCT02373332

- 6/20/21 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Fatty Acid Regulation of Platelet Function in Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT02373332

End period - Medications, Adverse Events, Transfusion History, Conclusion and Termination UK Essen Therapy of Chronic Cold Agglutinin Disease With Eculizumab NCT01303952

- 3/15/21 - 1 form, 4 itemgroups, 32 items, 2 languages
Itemgroups: Medications, Adverse Events, Transfusion history during the entry study, Conclusion of the Study and Termination
Study Type: Interventional Study Design: Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Official Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients With Cold Agglutinin Disease Using Eculizumab EudraCT-Nummer 2009-01696697 ClinicalTrials.gov-Identifier NCT01303952 https://clinicaltrials.gov/ct2/show/NCT01303952 Genehmigung durch Frau Ose

Eligibility Obstructive Sleep Apnea and Diabetes Mellitus NCT01136785

- 1/22/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effects of Continuous Positive Airway Pressure (CPAP)Treatment on Glucose Control; ODM derived from: https://clinicaltrials.gov/show/NCT01136785

Pharmacokinetics of Simvastatin When Coadministered With Albiglutide NCT01147692 - Screening - Vital Signs; General Medical History; Physical Exam

- 11/29/20 - 1 form, 5 itemgroups, 25 items, 1 language
Itemgroups: Administrative, Vital Signs (sitting), General Medical History, Physical Exam, Physical Exam
Study ID: 108366 Clinical Study ID: 108366 Study Title: An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01147692 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: simvastatin plus albiglutide Trade Name: simvastatin plus albiglutide Study Indication: Diabetes Mellitus, Type 2

Pharmacokinetics of Simvastatin When Coadministered With Albiglutide NCT01147692 - Pancreatitis

- 11/29/20 - 1 form, 12 itemgroups, 56 items, 1 language
Itemgroups: Administrative, Pancreatitis, Alcohol, Family History of Pancreatitis, Family History of Pancreatitis, Pancreatitis - Recent trauma/vascular invasive procedures or surgery, Symptoms of gastrointestinal illness associated with pancreatitis, Other symptoms associated with pancreatitis, Pancreatitis - Lab results (Biochemistry), Pancreatitis - Lab results (Biochemistry) , Pancreatitis - Additional Lab results (Biochemistry), Pancreatitis - Diagnostic studies
Study ID: 108366 Clinical Study ID: 108366 Study Title: An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01147692 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: simvastatin plus albiglutide Trade Name: simvastatin plus albiglutide Study Indication: Diabetes Mellitus, Type 2

Pharmacokinetics of Simvastatin When Coadministered With Albiglutide NCT01147692 - New Thyroid Nodules

- 11/29/20 - 1 form, 3 itemgroups, 22 items, 1 language
Itemgroups: Administrative , New Thyroid Nodules, Thyroid function
Study ID: 108366 Clinical Study ID: 108366 Study Title: An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01147692 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: simvastatin plus albiglutide Trade Name: simvastatin plus albiglutide Study Indication: Diabetes Mellitus, Type 2

Pharmacokinetics of Simvastatin When Coadministered With Albiglutide NCT01147692 - Liver Biopsy; Liver Events Assessment; Liver Imaging; Liver Event Follow-Up Chemistries

- 11/29/20 - 1 form, 10 itemgroups, 80 items, 1 language
Itemgroups: Administrative, Liver Biopsy, Liver Events Assessment, Liver Events, Liver Disease Medical Conditions, Drug related Liver Disease Conditions, Other Liver Disease Conditions, Other Medical Conditions, Liver Imaging, Liver event follow-up chemistries
Study ID: 108366 Clinical Study ID: 108366 Study Title: An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01147692 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: simvastatin plus albiglutide Trade Name: simvastatin plus albiglutide Study Indication: Diabetes Mellitus, Type 2

Pharmacokinetics of Simvastatin When Coadministered With Albiglutide NCT01147692 - Pregnancy Information

- 11/29/20 - 1 form, 6 itemgroups, 63 items, 1 language
Itemgroups: Administrative , Demography and Medical History (Pregnancy Notification Form), Pregnancy Information (Pregnancy Notification Form) , Demography and Medical History (Pregnancy Outcome Form), Child Information (Pregnancy Outcome Form), Pregnancy Outcome Information (Pregnancy Outcome Form)
Study ID: 108366 Clinical Study ID: 108366 Study Title: An Open-label, Sequential Study to Evaluate the Pharmacokinetics of Simvastatin When Coadministered With Albiglutide in Healthy Adult Subjects Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01147692 Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: simvastatin plus albiglutide Trade Name: simvastatin plus albiglutide Study Indication: Diabetes Mellitus, Type 2

Eligibility Subclinical Hypothyroidism NCT01853579

- 11/18/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
The TRUST Study - Depression Substudy; ODM derived from: https://clinicaltrials.gov/show/NCT01853579

Eligibility Non-proliferative Diabetic Retinopathy NCT02062034

- 11/18/20 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy; ODM derived from: https://clinicaltrials.gov/show/NCT02062034

Measurement Instrument Database for the Social Science (MIDSS) - Appraisal of Diabetes Scale (ADS)

- 9/13/20 - 1 form, 1 itemgroup, 7 items, 1 language
Itemgroup: DCAI-R (7/88)
Carey, M. P., Jorgensen, R. S., Weinstock, R. S., Sprafkin, R. P., Lantinga, L. J., Carnrike, C. L. M., Jr., Baker, M. T., & Meisler, A. W. (1991). Appraisal of Diabetes Scale (ADS). Measurement Instrument Database for the Social Science. Retrieved 13.09.20, from www.midss.ie Key references: Carey, M. P., Jorgensen, R. S., Weinstock, R. S., Sprafkin, R. P., Lantinga, L. J., Carnrike, C. L. M., Jr., Baker, M. T., & Meisler, A. W. (1991). Reliability and validity of the appraisal of diabetes scale. Journal of Behavioral Medicine, 14, 43-51. Garratt, A.M., L. Schmidt, and R. Fitzpatrick (2002) Patient-assessed health outcome measures for diabetes: a structured review. Diabetic Med., 19, 1-11. Trief, P.M., W. Grant, K. Elbert, and R.S. Weinstock (1998) Family environment, glycemic control, and the psychosocial adaptation of adults with diabetes. Diabetes Care 21, 241-245. Trief, P.M., C. Aquilino, K. Paradies, and R.S. Weinstock (1999) Impact of the work environment on glycemic control and adaptation to diabetes. Diabetes Care 22, 569-574. Primary use / Purpose: The Appraisal of Diabetes Scale (ADS) is a 7-item self-report scale assessing the individual's appraisal of his or her diabetes. Respondents rate each statement on a 5 point Likert scale. The scale's author state that the ADS can be incisive as a relatively quick (5 minute) screening tool to examine a patient’s adjustment to diabetes or risk for noncompliance with a care regimen. The test is easily administered (written or oral form) and is simple to score and interpret. The smaller the total score, the more positive the appraisal strategy. Thus, lower scores are better. Background: The Appraisal of Diabetes Scale (ADS) was developed and tested with 200 male subjects, two thirds of whom were taking insulin treatment with an mean age of 58 years. All subjects provided blood for routine monitoring of HbA1c, half the subjects completed the ADS as well as five other self-report measures, and the other half completed the ADS on three time points over the course of one week. No significant difference was observed between ADS scores for insulin-dependent and non-insulin-dependent subjects. The ADS has been used in studies parsing the effects of family environment (Trief et al. 1998) and work environment (Trief et al. 1999) on glycemic control and psychosocial adaptation in adults with diabetes. Psychometrics: The psychometric properties of the ADS are examined in Carey et al. (1991). Digital Object Identifier (DOI): http://dx.doi.org/10.13072/midss.274 Scoring the ADS is easy: 1. Reverse score items # 2 and 6. ADS2R = 5 - ADS2 ADS6R = 5 - ADS6 2. Then sum all items, using the reversed scored items 2 and 6. Total score = ADS1 + ADSR2 + ADS3 + ADS4 + ADS5 + ADSR6 + ADS7 There is no manual. Interpretation is straightforward: The smaller the total score, the more positive the appraisal strategy. Thus, lower scores are better.